Marry Brlas - Perrigo Company Independent Chairman of the Board
| PRGO Stock | USD 31.23 0.74 2.43% |
Chairman
Ms. Marry Laurie Brlas is Independent Chairman of the Board of Perrigo Company Public Limited Company. She was a director of Perrigo since August 2003 and was appointed Chairman of the Board in April 2016. Ms. Brlas served as Executive Vice President and Chief Financial Officer of Newmont Mining Corporation from September 2013 until October 2016, and she retired from Newmont Mining Corporation on December 31, 2016. From 2006 through 2013, Ms. Brlas held various positions with Cliffs Natural Resources, most recently as Executive Vice President and President Global Operations. Prior to this role, she served as Chief Financial Officer. Prior to that, Ms. Brlas served as Senior Vice President and Chief Financial Officer of STERIS Corporationrationration, a provider of healthcare products, from 2000 through 2006. From 1995 through 2000, Ms. Brlas held various positions with Office Max, Inc., most recently as Senior Vice President and Corporationrationrate Controller. Since June 2017, Ms. Brlas has served as a director of Albemarle Corporationrationration, a specialty chemicals company. Ms. Brlas also served as a director for Calpine from August 2016 to March 2018 and a director for Nova Chemicals from September 2008 to July 2009. since 2016.
| Age | 59 |
| Tenure | 8 years |
| Address | The Sharp Building, Dublin, Ireland, D02 TY74 |
| Phone | 353 1 709 4000 |
| Web | https://www.perrigo.com |
Perrigo Company Management Efficiency
The company has return on total asset (ROA) of 0.0164 % which means that it generated a profit of $0.0164 on every $100 spent on assets. This is way below average. Perrigo Company's management efficiency ratios could be used to measure how well Perrigo Company manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to -0.0028. In addition to that, Return On Capital Employed is likely to drop to 0.02. At this time, Perrigo Company's Other Assets are very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.63, while Total Assets are likely to drop about 5.7 B.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| G Prasad | Dr Reddys Laboratories | 59 | |
| Satish Reddy | Dr Reddys Laboratories | 52 | |
| Jack Bendheim | Phibro Animal Health | 77 | |
| Mary Luo | Amphastar P | 68 | |
| David Tsur | Kamada | 74 | |
| Robert Brown | ANI Pharmaceuticals | 67 | |
| David Stack | Pacira Pharmaceuticals | 74 | |
| David Hoover | Elanco Animal Health | 72 | |
| Jay Moorin | Eagle Pharmaceuticals | 62 | |
| Michael Heffernan | Collegium Pharmaceutical | 53 | |
| Ronald Lombardi | Prestige Brand Holdings | 60 | |
Management Performance
| Return On Equity | -9.0E-4 | ||||
| Return On Asset | 0.0164 |
Perrigo Company Leadership Team
Elected by the shareholders, the Perrigo Company's board of directors comprises two types of representatives: Perrigo Company inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perrigo. The board's role is to monitor Perrigo Company's management team and ensure that shareholders' interests are well served. Perrigo Company's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perrigo Company's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Hendrickson, President | ||
| Gary Cohen, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Svend Andersen, Executive Vice President and President - Consumer Healthcare International | ||
| Judy Brown, CFO and Executive VP | ||
| Laurie Brlas, Independent Director | ||
| Donal OConnor, Independent Director | ||
| James Michaud, Chief Human Resource Officer, Executive Vice President | ||
| Theodore Samuelsto, Independent Director | ||
| Scott Jamison, Executive Vice President General Manager - Nutritionals | ||
| Ellen Hoffing, Independent Director | ||
| Marc Coucke, Executive Vice President General Manager - Omega Pharma Business | ||
| Thomas Farrington, Executive Vice President, Chief Information Officer | ||
| Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare | ||
| Todd Kingma, Executive Vice President, General Counsel, Company Secretary | ||
| Rolf Classon, Independent Chairman of the Board | ||
| Patrick LockwoodTaylor, CEO President | ||
| Raymond Silcock, Chief Financial Officer, Executive Vice President | ||
| Shlomo Yanai, Independent Director Nominee | ||
| Michael Stewart, Senior Vice President - Global Human Resources | ||
| Jeffrey Kindler, Independent Director | ||
| Jacqualyn Fouse, Independent Director | ||
| Grainne Quinn, Executive Vice President Chief Medical Officer | ||
| Mary ReillyBrest, Director Development | ||
| Murray Kessler, President, Chief Executive Officer, Director | ||
| Erica Mann, Independent Director | ||
| Kyle Hanson, General VP | ||
| Richard Sorota, Executive Vice President, General Manager - of Consumer Self-Care Americas | ||
| Gary Kunkle, Lead Independent Director | ||
| Katherine Doyle, Independent Director | ||
| Joseph Papa, Chairman and CEO | ||
| Catherine Schmelter, Executive Optimization | ||
| Bradley Alford, Independent Director | ||
| Alison Ives, Executive Officer | ||
| Jeffrey Smith, Independent Director | ||
| James Dillard, Executive Vice President, President - Consumer Self-Care Americas | ||
| Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals | ||
| Orlando Ashford, Independent Director | ||
| Ronald Winowiecki, Acting CFO | ||
| Louis Yu, Executive Vice President - Global Quality | ||
| John Wesolowski, Executive Vice President and Presidentident - RX | ||
| Adriana Karaboutis, Independent Director | ||
| Michael Jandernoa, Independent Director | ||
| Shannon Hukill, Director Operations | ||
| Paul Weninger, Executive Vice President - Global Quality Operations | ||
| Herman Morris, Independent Director | ||
| Jatin Shah, Senior Vice President Chief Scientific Officer | ||
| Robert Willis, Chief Human Resource Officer, Executive Vice President | ||
| Theodore Samuels, Independent Director | ||
| Eduardo Bezerra, Executive CFO | ||
| Geoffrey Parker, Independent Director | ||
| Sharon Kochan, Executive Vice President, President - RX Pharmaceuticals | ||
| Marry Brlas, Independent Chairman of the Board | ||
| James III, Ex Americas | ||
| Bradley Joseph, Vice Communications | ||
| Ronald Janish, Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer | ||
| Uwe Rohrhoff, President CEO, Director |
Perrigo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perrigo Company a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.0E-4 | ||||
| Return On Asset | 0.0164 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 7.66 B | ||||
| Shares Outstanding | 135.52 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 99.47 % | ||||
| Number Of Shares Shorted | 3.86 M | ||||
| Price To Earning | 23.57 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Perrigo Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Perrigo Company PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Perrigo Company information on this page should be used as a complementary analysis to other Perrigo Company's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Perrigo Stock analysis
When running Perrigo Company's price analysis, check to measure Perrigo Company's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perrigo Company is operating at the current time. Most of Perrigo Company's value examination focuses on studying past and present price action to predict the probability of Perrigo Company's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perrigo Company's price. Additionally, you may evaluate how the addition of Perrigo Company to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Perrigo Company's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo Company. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo Company listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Dividend Share 1.092 | Earnings Share (0.03) | Revenue Per Share 34.409 | Quarterly Revenue Growth 0.001 |
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo Company's value that differs from its market value or its book value, called intrinsic value, which is Perrigo Company's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo Company's market value can be influenced by many factors that don't directly affect Perrigo Company's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo Company's value and its price as these two are different measures arrived at by different means. Investors typically determine if Perrigo Company is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo Company's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.